English, Article edition: Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis Dirk Mueller; Eva Weyler; Afschin Gandjour

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119315
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
Author
  • Dirk Mueller
  • Eva Weyler
  • Afschin Gandjour
Physical Description
  • article
Notes
  • Background: The German osteology umbrella organization, Dachverband Osteologie (DVO), has published a new guideline for the secondary prevention of osteoporotic fractures. According to the guideline, women are screened using dual x-ray absorptiometry (DXA). Those with an absolute 10-year fracture risk >=​30% are treated with bisphosphonates such as alendronate or risedronate for 4 years or with teriparatide for 18 months. Objective: To determine the cost effectiveness of the screen-and-treat strategy versus no intervention in women of the general population aged 50-90 years in Germany. Methods: Cost-utility and budget-impact analyses were performed from the perspective of the statutory health insurance (SHI). A Markov model with a 1-year cycle length simulated costs and benefits (QALYs), discounted at 3%, over a lifetime horizon. The number of women correctly diagnosed by pre-tests and DXA as having a 10-year fracture risk of >=​30% was estimated for different age groups (50-60, 60-70, 70-80 and 80-90 years). Incremental cost-effectiveness ratios (ICERs) were calculated; all costs are presented in _, year 2006 values. Robustness of the results was tested by a probabilistic Monte Carlo simulation. Results: Alendronate was the most cost-effective drug in all age groups; the ICERs were _3849, _16_589, _6600 and _2337 per QALY for 50-, 60-, 70- and 80-year-old women, respectively, followed by risedronate. Teriparatide was dominated in every age group. Implementing the screen-and-treat strategy would result in annual costs of _175 million for alendronate (_181 million for risedronate) or 0.14% of the SHI annual budget. Results were robust in the sensitivity analysis. Conclusion: While the screen-and-treat strategy would result in a substantial cost increase for the SHI, the use of alendronate within such a strategy appears cost effective when compared with many generally accepted medical interventions.
  • Alendronic-acid, Bone-mineral-density, Cost-utility, Diagnostic-Tests, Elderly, Fracture, Osteoporosis, Risedronic-acid, Screening, Teriparatide, Postmenopausal-osteoporosis, Postmenopausal-osteoporosis
  • RePEc:wkh:phecon:v:26:y:2008:i:6:p:513-536
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment